📊 TENX Key Takeaways
Is Tenax Therapeutics, Inc.. (TENX) a Good Investment?
Tenax Therapeutics is a pre-revenue pharmaceutical company burning $35.8M annually with zero commercial revenue, leaving approximately 2.7 years of cash runway at current burn rates. While the balance sheet shows minimal debt and $97.6M in cash, the company faces existential risk without imminent revenue generation or capital raise. The persistent losses and lack of positive fundamentals indicate a distressed development-stage biotech with unclear path to profitability.
Why Buy Tenax Therapeutics, Inc.. Stock? TENX Key Strengths
- Zero long-term debt with pristine balance sheet
- Exceptional liquidity with $97.6M cash and 14.56x current ratio
- Minimal capital expenditure requirements ($2.8K) reducing near-term cash needs
TENX Stock Risks: Tenax Therapeutics, Inc.. Investment Risks
- Zero revenue generation - no commercial products generating sales
- Negative operating cash flow of -$35.8M annually indicates accelerating cash depletion
- Limited runway: current cash reserves deplete within 2.7 years at present burn rate
- Significant operating losses (-$56.4M) with negative ROE (-54.2%) and ROA (-50.5%)
- No identifiable near-term catalysts for revenue generation from available data
Key Metrics to Watch
- Cash burn rate trend and quarterly cash balance depletion
- Product pipeline development status and regulatory milestone progress
- Clinical trial advancement and pathway to FDA approval
- Capital raise announcements and dilutive financing events
- Operating cash flow trajectory toward positive inflection
Tenax Therapeutics, Inc.. (TENX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.56x current ratio provides a solid financial cushion.
TENX Profit Margin, ROE & Profitability Analysis
TENX vs Healthcare Sector: How Tenax Therapeutics, Inc.. Compares
How Tenax Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tenax Therapeutics, Inc.. Stock Overvalued? TENX Valuation Analysis 2026
Based on fundamental analysis, Tenax Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tenax Therapeutics, Inc.. Balance Sheet: TENX Debt, Cash & Liquidity
TENX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tenax Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
TENX Revenue Growth, EPS Growth & YoY Performance
TENX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$3.6M | $-0.19 |
| Q2 2025 | N/A | -$3.6M | $-0.27 |
| Q1 2025 | N/A | -$3.8M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tenax Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
TENX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tenax Therapeutics, Inc.. (CIK: 0000034956)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TENX
What is the AI rating for TENX?
Tenax Therapeutics, Inc.. (TENX) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TENX's key strengths?
Claude: Zero long-term debt with pristine balance sheet. Exceptional liquidity with $97.6M cash and 14.56x current ratio.
What are the risks of investing in TENX?
Claude: Zero revenue generation - no commercial products generating sales. Negative operating cash flow of -$35.8M annually indicates accelerating cash depletion.
What is TENX's revenue and growth?
Tenax Therapeutics, Inc.. reported revenue of $0.0.
Does TENX pay dividends?
Tenax Therapeutics, Inc.. does not currently pay dividends.
Where can I find TENX SEC filings?
Official SEC filings for Tenax Therapeutics, Inc.. (CIK: 0000034956) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TENX's EPS?
Tenax Therapeutics, Inc.. has a diluted EPS of $-1.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TENX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tenax Therapeutics, Inc.. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TENX stock overvalued or undervalued?
Valuation metrics for TENX: ROE of -54.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TENX stock in 2026?
Our dual AI analysis gives Tenax Therapeutics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TENX's free cash flow?
Tenax Therapeutics, Inc..'s operating cash flow is $-35.8M, with capital expenditures of $2.8K.
How does TENX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -54.2% (avg: 15%), current ratio 14.56 (avg: 2).